A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

16387BH-30643-01-NCT06706076OpenA Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)BH-30643-01NCT06706076IndustrialAdultTreatmentI/IIGlobalLungKim, ChulGeorgetown University Medical Center : Jailyn Izu; Lombardi Comprehensive Cancer Center : Jailyn IzuThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS17685Jailyn IzuJailyn Izuji241@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>